Citations

Clear

2303 citation(s) found for "Yu, Edward".

Thirty-Day Outcomes Following Pediatric Cranioplasty: An Analysis of 249 Patients
Gharavi, Aidin , Patel, Hiteshi, Polites, Stephanie F. , Ahn, Edward S. , Gharavi, Aidin , Habermann, Elizabeth B. , Mardini, Samir , Gibreel, Waleed

Mayo Clinic

Journal of Craniofacial Surgery | August 22, 2025 | Volume: 36 | Issue: 7 | Pages: 2396-2400

10.1097/scs.0000000000011759 | PMID 40845319 Get It

Surgical outcomes and perioperative factors associated with pediatric cranioplasty remain incompletely understood. The authors queried the National Surgical Quality Improvement Program-Pediatric (NSQIP-P) database to evaluate outcomes and intraoperative/postoperative blood transfusions in patients undergoing cranioplasty between 2019 and 2023. A total of 249 patients (mean age 9.1 ± 5.4 y) were included. Most cranioplasties (70.7%) utilized alloplastic materials compared with autologous. Blood transfusion was required in 24.1% of cases, predominantly on the day of surgery (86.7%). Multivariable analysis identified age (OR: 0.86 per year, 95% CI: 0.80–0.93, P < 0.001) and cranioplasty size >5 cm (versus ≤5 cm) (OR: 2.10, 95% CI: 1.01–4.50, P = 0.049) as predictors of transfusion. The 30-day unplanned readmission rate was 5.3% at a mean of 14.6 ± 7.9 days from surgery, most commonly for a surgical site infection (33.0%). The 30-day unplanned reoperation rate was 2.9%, at a mean of 10.2 ± 5.6 days. Autologous cranioplasty was not associated with higher odds of readmission (OR: 0.79, 95% CI: 0.25–2.13, P = 0.66) or reoperation (OR: 5.04, 95% CI: 0.96–36.99, P = 0.07) compared with alloplastic cranioplasty. Rates of readmission and reoperation following pediatric cranioplasty are comparable to other complex craniofacial procedures. Younger age and larger cranioplasty size are associated with higher rates of blood transfusion. Our results show that autologous reconstruction is not associated with higher short-term complication rates compared with alloplastic reconstruction, although future studies are still needed to further the understanding of the optimal cranioplasty material.
Associations of High Attenuation Area–Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
Debban, Catherine L., Guzman, Daniel E., Hannan, Riley T. , Salvatore, Mary , Zhang, David , Podolanczuk, Anna J. , Ma, Shwu‐Fan , Huang, Yong , Rotter, Jerome I., Dubin, Ruth F. , Wang, Jennifer M. , Han, MeiLan K., Noth, Imre , Woodruff, Prescott G. , Ortega, Victor E. , Fanburg–Smith, Julie C. , Stelow, Edward B. , Moskaluk, Christopher A. , Hoffman, Eric A. , Barr, R. Graham , Hannan, Riley T , Zhang, David , Podolanczuk, Anna J , Ma, Shwu-Fan , Pugashetti, Janelle Vu , Wang, Jennifer M , Oldham, Justin M , Hoffman, Eric A , Garcia, Christine K , Kim, John S. , McGroder, Claire F. , Duprez, Daniel A. , Sturek, Jeffrey M , Rich, Stephen S. , Rotter, Jerome I. , Deo, Rajat , Han, MeiLan King , Bowler, Russell P. , Ganz, Peter , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 22, 2025 | Volume: 211 | Issue: 10 | Pages: 1811-1822

10.1164/rccm.202503-0610oc | PMID 40845333 Get It

Abstract Rationale High-attenuation area (HAA) is a computed tomography (CT) tool that correlates with lung inflammation and fibrosis. Systemic molecular correlates of HAA (e.g., plasma proteins) may inform biological processes involved in interstitial lung disease. Objectives To identify plasma proteins that associate with HAA and correlate with a higher probability of developing new-onset fibrotic or subpleural interstitial lung abnormalities (ILAs). Methods Plasma protein levels were measured using a semiquantitative aptamer-based platform in MESA (the Multi-Ethnic Study of Atherosclerosis; N = 5,486) and SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study; N = 1,781). Linear regression models identified HAA-associated proteins after adjustment for demographic and socioeconomic factors, CT scanner parameters, study center, and batch. Associations of HAA-related proteins with new-onset fibrotic or subpleural ILAs were examined in MESA participants with ILA assessments on full-lung CT 10 years later. Immunohistochemical staining of select proteins was performed in lung tissue from pulmonary fibrosis cases. Measurements and Main Results There were 75 proteins detected that were significantly associated with HAA in MESA and SPIROMICS. Gene Ontology analysis of these proteins identified processes involved in immune cell chemotaxis and cellular growth and apoptosis. Seven proteins were associated with a higher probability of new-onset fibrotic or subpleural ILAs in MESA, and two of these, junctional adhesion molecule-like protein and GTP cyclohydrolase 1 feedback regulatory protein, stained in areas of fibrosis in lung tissue from patients with interstitial lung disease. Conclusions Plasma proteins associated with more HAA are involved in immune and cellular processes and associate with new-onset fibrotic-subpleural ILA.
Early Thrombolysis and Outcomes in Central Retinal Artery Occlusion: An Individual Participant Data Meta-Analysis
Xie, Jim Shenchu , Chaban, Yuri V. , Lusterio, Adrien , Kaur, Hargun , Motekalem, Yasmin, Zeraatkar, Dena , Althaus, Katharina , Malbin, Brett , Nolte, Christian H. , Pettersen, Jacqueline A. , Woo, Se Joon , Chen, Celia S. , Khrlobyan, Manya, Sangha, Navdeep , Jurado, Elena Ardila, Mattle, Heinrich P. , Nedelmann, Max, Spitzer, Martin S. , Poli, Sven , Hametner, Christian , Baumgartner, Philipp , Kook, Lucas , Dumitrascu, Oana M. , Margolin, Edward , Xie, Jim S , Zaslavsky, Kirill , Chaban, Yuri V , Lusterio, Adrien , Popovic, Marko M , Althaus, Katharina , Malbin, Brett , Nolte, Christian H , Scheitz, Jan F , Pettersen, Jacqueline A , Leker, Ronen R , Kim, Joonhyung , Woo, Se Joon , Chen, Celia , Feltgen, Nicolas , Sangha, Navdeep , Arnold, Marcel , Mattle, Heinrich , Heldner, Mirjam R , Cordonnier, Charlotte , Poli, Sven , Hametner, Christian , Baumgartner, Philipp , Wegener, Susanne , Kook, Lucas , Shahjouei, Shima , Dumitrascu, Oana M , Margolin, Edward M , Heldner, Mirjam R. , Shahjouei, Shima , Michel, Patrik

Mayo Clinic

Stroke | August 20, 2025 | Volume: 56 | Issue: 11 | Pages: 3175-3186

10.1161/strokeaha.124.049955 | PMID 40832714 Get It

BACKGROUND: This individual participant data meta-analysis aimed to determine whether time to treatment influences the effect of intraarterial thrombolysis (IAT), intravenous thrombolysis, and conservative standard therapy on visual outcomes in nonarteritic central retinal artery occlusion. METHODS: We searched MEDLINE, CENTRAL, and Embase up to June 2023 for studies reporting treatment modality and peri-treatment best-corrected visual acuity (BCVA) for ≥5 participants, excluding patients with nonsevere vision loss (BCVA <1.0 logarithm of the minimum angle of resolution [logMAR]) or treated after 24 hours of symptom onset. The primary outcome was recovery from severe vision loss (final BCVA <1.0 logMAR). We used mixed-effect models and local polynomial regression to investigate nonlinear relationships between time to treatment and recovery from severe vision loss. RESULTS: Of 4074 screened studies, individual participant data were sought from 52, with 35 contributing individual participant data for 1038 participants. In total, 783 patients met inclusion criteria (age, 64.8±13.3 years; 35.5% female; baseline BCVA, 2.3±0.5 logMAR). For every hour decrease in time to treatment, thrombolysis was associated with greater improvement in BCVA (intraarterial, 0.02 logMAR [95% CI, 0–0.04]; intravenous, 0.04 logMAR [95% CI, 0.00–0.07]) than conservative standard therapy (0.01 logMAR [95% CI, 0–0.02]). A nonlinear relationship was detected for intraarterial thrombolysis with a changepoint at 8 hours (95% CI, 6.7–9.4). Thrombolysis was associated with increased recovery from severe vision loss compared with conservative standard therapy (intraarterial within 6 hours: odds ratio, 2.72 [95% CI, 1.02–7.28], 27.2% versus 12.0%; intravenous within 4.5 hours: odds ratio, 3.32 [95% CI, 1.24–8.92], 28.8% versus 11.1%). Findings were consistent in subgroup analysis restricted to patients receiving recombinant tissue-type plasminogen activator. Monte-Carlo simulations showed that a randomized controlled trial would require 95 participants per group to achieve 80% power to detect an odds ratio of 3.0 for recovery from severe vision loss. CONCLUSIONS: Early intervention in nonarteritic central retinal artery occlusion is associated with improvement in visual recovery, with intraarterial thrombolysis and intravenous thrombolysis outperforming nonthrombolytic treatments. These findings warrant confirmation in sufficiently powered randomized controlled trials.
Transfusion of Amustaline/Glutathione Pathogen-reduced Red Blood Cells in Cardiac Surgery: A Randomized Phase 3 Clinical Trial
Sekela, Michael , Snyder, Edward L. , Toyoda, Yoshiya , Alsammak, Mohamed , Sodha, Neel R. , Beaver, Thomas M. , Pelletier, J. Peter R. , Gorham, James D. , McNeil, John W. , Pearl, Ronald G. , Nuttall, Gregory A. , Reece, T. Brett , Collaborators, and the ReCePI Study, Sekela, Michael E , Welsby, Ian J , Alsammak, Mohamed , Sodha, Neel R , Beaver, Thomas M , Pelletier, J Peter R , Gorham, James D , McNeil, John S , Sniecinski, Roman M , Nuttall, Gregory A , Sarode, Ravi , Benjamin, Richard J , Collaborators, and the ReCePI Study

Mayo Clinic

Anesthesiology | August 12, 2025 | Volume: 143 | Issue: 5 | Pages: 1196-1210

10.1097/aln.0000000000005716 | PMID 41085306 Get It

Background: Transfusion has a persistent low risk of transfusion-transmitted infection and transfusion-associated graft- versus -host disease that may be addressed using pathogen reduction. The Red Cell Pathogen Inactivation (ReCePI) trial tested whether amustaline/glutathione pathogen-reduced red cells are noninferior to conventional transfusions for support of acute surgical blood loss. Methods: A phase 3, double-blinded, noninferiority trial randomized cardiac or thoracic–aorta surgery patients with increased risk of red cell transfusion to receive pathogen-reduced or conventional red cells during and for 7 days postsurgery. The primary endpoint was the proportion of patients with acute kidney injury (AKI), which is defined as an increase from baseline of greater than or equal to 0.3 mg/dl serum creatinine within 48 h of surgery. Noninferiority was claimed if the upper bound 95% CI of the treatment difference was less than half (50%) of the observed conventional arm incidence. Adverse events and treatment-emergent red cell antibodies were assessed for 28 and 75 days, respectively. Results: A total of 581 subjects were randomized, and 321 (55%) were transfused with study red cells. Transfused subjects in both arms had similar baseline demographics, medical histories, hemoglobin levels, and surgical procedures. Hemoglobin day 3 nadir levels (8.6 g/dl [7.8 to 9.2] in the pathogen-reduced arm; 8.4 g/dl [7.8 to 9.3] in the conventional arm; P = 0.52) were comparable. Incidence of AKI by 48 h was 46 of 157 (29.3%) in the pathogen-reduced arm and 45 of 161 (28.0%) in the conventional arm (treatment difference, 0.7%; 95% CI, −8.9 to 10.4%; noninferiority margin, 14.0%; P = 0.001 for noninferiority). AKI within 7 days by Kidney Disease Improving Global Outcomes staging criteria was not different (59 of 159 [37.1%] in the pathogen-reduced arm; 55 of 162 [34.0%] in the conventional arm; P = 0.53), but stage III was more common in the pathogen-reduced arm (pathogen-reduced arm, 15 of 159 [9.4%]; conventional arm, 7 of 162 [4.3%]; P = 0.075). Of 159 pathogen-reduced red cell recipients, 5 (3.1%) developed specific, low-titer antibodies without evidence of hemolysis. Conclusions: The incidence of AKI in recipients of pathogen-reduced red cells was noninferior to conventional red cell transfusion. Treatment-emergent antibodies were uncommon and not clinically significant.
Alcohol use disorder, but not current alcohol use is associated with falls among people with HIV in care
Dai, Mindy , Chander, Geetanjali , Webel, Allison R. , Whitney, Bridget M. , Christopoulos, Katerina , Moore, Richard D. , Keruly, Jeanne , Bamford, Laura , Cachay, Edward R. , McCaul, Mary E. , Fredericksen, Rob J. , Yendewa, George A. , Saag, Michael S. , Crane, Heidi M. , Cachay, Edward, Delaney, Joseph A. , Mayer, Kenneth Hugh , Christopoulos, Katerina A. , Napravnik, Sonia , Lesko, Catherine R. , Drumright, Lydia N.

Mayo Clinic

AIDS | August 12, 2025 | Volume: 39 | Issue: 14 | Pages: 2094-2102

10.1097/qad.0000000000004317 | PMID 40792693 Get It

Background: Current understanding of associations between alcohol use and falls among people with HIV (PWH) is limited due to few and inconsistent studies. Given the prevalence of heavy episodic alcohol use reported among PWH, this remains an important question. Methods: Alcohol use was measured using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) and self-reported alcohol use treatment and/or diagnosis of alcohol use disorder (collectively AUD) among PWH at eight CFAR Network of Integrated Clinical Systems (CNICS) sites from 2021 to 2024. Falls were self-reported using the components of the Falls Risk for Older People in the Community (FROP-Com) questionnaire. Cross-sectional associations between alcohol use and falls were examined using relative risk models adjusted for age, sex, race/ethnicity, and geographic location. Results: Among 5729 PWH, mean age was 55 years; 42% reported White and 41% reported Black/African American race/ethnicity; and 81% were male. Mean AUDIT-C score was 1.9 (range: 0–12); 27% reported heavy episodic drinking; 22% had AUD; and 22% reported falling in the past year. Reporting at least one fall in the past year was not associated with any measure of current alcohol use. AUD was associated with reporting at least one fall [prevalence ratio = 1.54; 95% confidence interval (CI) 1.39–1.70] and number of falls [one fall: prevalence ratio = 1.27 (95% CI: 1.08–1.50); at least two falls: prevalence ratio = 1.84 (95% CI: 1.58–2.15)]. Conclusion: Among PWH, 22% reported falling, which was associated with AUD, but not current alcohol use, suggesting that a mechanism other than acute intoxication could be responsible. Further longitudinal research is warranted to explore mechanisms for why AUD, but not current alcohol use, is associated with falls.
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Bruin, Hannah de , Groot, Colin , Barthel, Henryk , Bischof, Gérard N. , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Day, Gregory S. , Dyck, Christopher H. van , Fredericks, Carolyn , Fryer, Tim D. , Graff‐Radford, Jonathan , Hobbs, Diana A. , Hoenig, Merle C. , Josephs, Keith A. , Katsumi, Yuta , Joie, Renaud La , Xiong, Chengjie , Malpetti, Maura , McGinnis, Scott M., Mecca, Adam P. , O’Brien, John T. , Putcha, Deepti , Rabinovici, Gil D. , Rahmouni, Nesrine , Rullmann, Michael , Saur, Dorothee , Servaes, Stijn , Sintini, Irene , Stevenson, Jenna , Stomrud, Erik , Strandberg, Olof, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip S.J. , Whitwell, Jennifer L. , Yong, Keir , de Bruin, Hannah , Brendel, Matthias , Cash, David M , Coath, William , Dickerson, Bradford Clark , van Eimeren, Thilo , van der Flier, Wiesje M , Fredericks, Carolyn A , Gordon, Brian A , Graff-Radford, Jonathan , Grinberg, Lea , Hansson, Oskar , Irwin, David J , Josephs, Keith A , Katsumi, Yuta , La Joie, Renaud , Lee, Edward B , Xiong, Chengjie , Malpetti, Maura , Mohanty, Rosaleena , O'Brien, John Tiernan , Palleis, Carla , Phillips, Jeffrey S , Putcha, Deepti , Rosa-Neto, Pedro , Schott, Jonathan M , Schroeter, Matthias L , Smith, Ruben , Spina, Salvatore , Therriault, Joseph , Whitwell, Jennifer , Yong, Keir X X , Franzmeier, Nicolai , Day, Gregory S , Stomrud, Erik , Rabinovici, Gil D , Blazhenets, Ganna , Boellaard, Ronald , Doering, Elena , Drzezga, Alexander E. , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Lee, Edward B. , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Perneczky, Robert , Rowe, James B. , Sabri, Osama , Schildan, Andreas , Schott, Jonathan M. , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Visser, Denise , Wolk, David A. , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Brain | August 8, 2025 | Volume: 148 | Issue: 11 | Pages: 3893-3912

10.1093/brain/awaf279 | PMID 40810361 Get It

Abstract The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicentres. However, given the limited spatial heterogeneity of tau in typical AD, atypical (non-amnestic-predominant) AD variants with distinct tau patterns provide a key opportunity to investigate the universality of connectivity as a scaffold for tau progression. In this large-scale, multicentre study across 14 international sites, we included cross-sectional tau-PET data from 320 individuals with atypical AD (n = 139 posterior cortical atrophy/PCA-AD; n = 103 logopenic variant primary progressive aphasia/lvPPA-AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS-AD), with a subset of individuals (n = 78) having longitudinal tau-PET data. Additionally, as an independent sample, we included regional post-mortem tau stainings from 93 atypical AD patients from two sites (n = 19 PCA-AD, n = 32 lvPPA-AD, n = 23 bvAD, n = 19 CBS-AD). Gaussian mixture modelling was used to harmonize different tau-PET tracers by transforming tau-PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether brain regions with stronger resting-state functional MRI-based functional connectivity, derived from healthy elderly controls in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), showed greater covariance in cross-sectional and longitudinal tau-PET and post-mortem tau pathology. Furthermore, we examined whether functional connectivity of tau-PET epicentres (i.e. the top 5% of regions with the highest baseline tau load) and tau-PET accumulation epicentres (i.e. the top 5% of regions with the highest tau accumulation rates) was associated with cross-sectional and longitudinal tau patterns. Our findings show that tau-PET epicentres aligned with clinical variants, e.g. a visual network predominant pattern in PCA-AD (‘visual AD’) and left-hemispheric temporal predominance, particularly within the language network, in lvPPA-AD (‘language AD’). Moreover, more strongly functionally connected regions showed correlated concurrent tau-PET levels (confirmed with post-mortem data) and tau-PET accumulation rates. The functional connectivity profile of tau-PET epicentres and accumulation epicentres corresponded to tau-PET progression patterns, with higher tau-PET levels and accumulation rates in functionally close regions, and lower tau-PET levels and accumulation rates in functionally distant regions. Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicentres, across all AD clinical variants. Since tau proteinopathy is a major driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant-specific end points in clinical trials.
Factors Influencing the Duration From the Initiation of Surgical Evaluation to Final Intervention in Pediatric Epilepsy Surgery
Al‐Ramadhani, Ruba , Hyslop, Ann , Caraway, Avery Robert, Ostendorf, Adam P. , Alexander, Allyson , Depositario‐Cabacar, Dewi F., Karia, Samir , Tatachar, Priyamvada, Bolton, Jeffrey , Pichon, P, Shrey, Daniel W. , Romanowski, Erin Fedak , Auguste, Kurtis I. , Bernardo, Danilo , Singh, Rani K., Reddy, Shilpa B. , Ganesh, Abhinaya, Ciliberto, Michael A. , Samanta, Debopam , Arredondo, Kristen H. , Marashly, Ahmad , Wagner, Janelle L. , Miller, D. , Galán, Fernando , Perry, Μ. Scott , Caraway, Avery R. , Wong-Kisiel, Lily C. , Gonzalez-Giraldo, Ernesto , Samanta, Debopam , Galan, Fernando N , Hyslop, Ann , Miller, Derryl J , Caraway, Avery Robert , Novotny, Edward J. , Eschbach, Krista , Wong‐Kisiel, Lily C. , Depositario‐Cabacar, Dewi, Oluigbo, Chima , Karakas, Cemal , Tatachar, Priyamvada , McNamara, Nancy , Gonzalez‐Giraldo, Ernesto , Javarayee, Pradeep , Lin, Jenny J. , Coryell, Jason , Ganesh, Abhinaya, Grinspan, Zachary M. , Armstrong, Dallas , Abel, Taylor J.

Mayo Clinic

Annals of the Child Neurology Society | August 6, 2025 | Volume: 3 | Issue: 3 | Pages: 188-200

10.1002/cns3.70027 | PMID 42563855 Get It

ABSTRACT Rationale Longer duration of epilepsy before surgery is a predictor of poor outcome. While referral delays of surgical candidates are well documented, factors causing delay during the presurgical evaluation remain unclear and may vary depending on institutional characteristics. By benchmarking the duration of presurgical evaluation across multiple centers and identifying patient and evaluation characteristics contributing to duration, we can ascertain best practices and address modifiable contributors to reduce delays. Methods We queried the Pediatric Epilepsy Research Consortium Surgery Database, a prospective, observational multicenter study enrolling children 0–18 years at 27 US pediatric epilepsy centers, for all patients undergoing initial presurgical evaluation for drug‐resistant epilepsy (DRE). We included patients with completed evaluations and data on duration from initiation of presurgical evaluation to final surgical decision. We compared patient characteristics and evaluation components between those with long duration evaluations (> 75% quartile) and those with short evaluations (< 25% quartile). Akaike information criteria selection identified variables associated with longer duration. From these, we developed a logistic prediction model for evaluation duration, using a random 80/20 training/testing split of the entire cohort. The model was tested among institutions with ≥ 10 patients in the cohort to assess its accuracy in predicting long durations. Linear models for each site assessed each variable's impact on duration. Variables with < 10% of the patient population at each site were excluded. Beta values were compared to identify intra‐ and inter‐institution variability and to delineate institutions with the shortest added duration for each variable. Results Of 2318 patients undergoing surgical evaluation, 1655 (71%) from 23 sites had complete data. Median evaluation duration was 8 weeks (interquartile range 3–22); 453 (27%) were short‐duration evaluations and 414 (25%) were long‐duration evaluations. Multiple patient and evaluation characteristics were associated with duration (Table 1). Table 6 provides the average duration each variable contributes to evaluation by site, highlighting the shortest durations compared with other groups. Conclusions Duration of presurgical evaluation for DRE can be accurately modeled using multiple patient characteristics and testing strategies commonly employed in epilepsy surgery evaluations. This predictive model can not only estimate evaluation duration but also identify opportunities to improve systemic efficiency. Institution‐level modeling identifies specific program strengths, providing an opportunity to learn from successful processes. Subsequent research will focus on institutional process mapping to better understand systemic practices that lead to improved efficiencies, then sharing these processes across the consortium to shorten evaluation durations.
Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia‐specific perspectives
Carrillo, Marı́a C., Chen, Christopher , Choi, Seong Hye , Fontana, Igor C. , Graff‐Radford, Jonathan, Heidebrink, Judith L. , Hu, Chaur‐Jong , Ihara, Ryoko , Ip, Fanny C.F., Fitri, Fasihah Irfani , Jack, Clifford R. , Yoon, Soo Jin , Jia, Jianping , Kandiah, Nagaendran, Kowa, Hisatomo , Joie, Renaud La , Noritake, Ryoji, Okonkwo, Ozioma C. , Raman, Rema , Shen, Yong , Simuni, Tanya, Snyder, Heather M. , Sriwannopas, Orapitchaya, Wang, Huali , Zhou, Jin , Sexton, Claire E. , Carrillo, María C. , Simuni, Tanya , Chen, Christopher , Mahinrad, Simin , Jack, Clifford R , La Joie, Renaud , Simuni, Tanya , Iwatsubo, Takeshi , Sperling, Reisa Anne , Algeciras‐Schimnich, Alicia , Arai, Hidenori , Barron, Anna M. , Benzinger, Tammie L.S. , Graff‐Radford, Jonathan , Grill, Joshua D. , Ikeuchi, Takeshi , Iwata, Atsushi , Kandiah, Nagaendran , Kim, SangYun , Niimi, Yoshiki , Palmqvist, Sebastian , Rafii, Michael S. , Stoeckel, Luke E. , Flier, Wiesje M. van der , Wilcock, Donna M. , Zetterberg, Henrik , Mahinrad, Simin

Mayo Clinic

Alzheimer's & Dementia | August 5, 2025 | Volume: 21 | Issue: 8 | Pages: No page available

10.1002/alz.70536 | PMID 40760693 Get It

Abstract The landscape of Alzheimer's disease (AD) and related dementias (ADRD) diagnosis is evolving rapidly, driven by advances in disease understanding, biomarker tools, and disease‐modifying therapies. Modern diagnostic approaches emphasize biological precision, early detection, and dynamic frameworks that adapt to treatment‐induced changes in disease biology. These frameworks enable opportunities for personalized interventions—encompassing pharmacological and non‐pharmacological strategies—and for enhanced clinical trial design. However, implementing these advancements globally is influenced by diverse cultural, infrastructural, and regulatory factors. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis, held in Japan, provided a unique platform to explore these global dynamics, particularly from an Asian perspective. This article highlights key discussions from the conference, exploring the role of biomarker‐based diagnostic frameworks in shaping the future of AD/ADRD research, diagnosis, and treatment. We highlight regional challenges and successes and emphasize ethical considerations and practical strategies needed to ensure equitable access to diagnostic and therapeutic innovations. Highlights Advances in biomarkers are reshaping Alzheimer's disease diagnosis and treatment. Modern diagnostic frameworks highlight biological precision, early detection, and dynamic frameworks. The 2024 Alzheimer's Association International Conference Advancements: Modernizing Diagnosis explored challenges and opportunities in global biomarker implementation. The conference explored geographic‐specific impacts, focusing on Asia.
Design considerations for C9orf72 disease prevention trials
Benatar, Michael , Staffaroni, Adam M. , Wuu, Joanne , McDermott, Michael P. , Quintana, Melanie , Swidler, Jean , Andersen, Gail, Huey, Edward D. , Turner, Martin R. , Macklin, Eric A. , Gendron, Tania, Onyike, Chiadi U. , Rosen, Howard J. , Heuer, Hilary W. , Grignon, Anne‐Laure , Dave, Kuldip D. , Balas, Calaneet, Satlin, Andrew , Dunn, Billy , Dacks, Penny A. , Boxer, Adam L. , Berry, James D , McMillan, Corey T , Gendron, Tania F , Onyike, Chiadi , Rosen, Howard J , Heuer, Hilary W , Grignon, Anne-Laure , Satlin, Andrew , Dacks, Penny , Boxer, Adam , Turner, Martin R , Wuu, Joanne , Andersen, Gail, Berry, James D. , McMillan, Corey T. , Gendron, Tania F. , Gleixner, Amanda M.

Mayo Clinic

Brain | August 3, 2025 | Volume: 148 | Issue: 11 | Pages: 3844-3855

10.1093/brain/awaf290 | PMID 40794569 Get It

Abstract The idea that it might be possible to prevent some forms of amyotrophic lateral sclerosis and frontotemporal dementia has finally come of age. The hexanucleotide repeat expansion in the C9orf72 gene accounts for ∼10% of all amyotrophic lateral sclerosis and 10%–15% of all frontotemporal dementia diagnoses, with the two clinical syndromes co-manifesting in a significant number of patients. As a result, clinically unaffected carriers of pathogenic C9orf72 repeat expansions are currently the largest identifiable population at significantly elevated risk for both amyotrophic lateral sclerosis and frontotemporal dementia, and in whom it might be possible to prevent the emergence of clinically manifest disease. Strategies for the design of disease prevention trials among clinically unaffected C9orf72 carriers have begun to emerge separately in the amyotrophic lateral sclerosis and frontotemporal dementia fields. However, recognition of the need to define neurodegenerative diseases based on biology underscores the need to consider all potential clinical manifestations of a C9orf72 repeat expansion together, rather than the traditional siloed approach of focusing on only amyotrophic lateral sclerosis or only frontotemporal dementia. Indeed, emerging clinical and biological markers that might be used to quantify pre-symptomatic disease progression and to predict the short-term risk of phenoconversion to clinically manifest disease are shared across the phenotypic spectrum. Given the anticipated progress in the development of therapeutic strategies to target the C9orf72 repeat expansion, and the enthusiasm for prevention trials among the unaffected C9orf72 repeat expansion carrier population, now is the time to begin work on the design of disease prevention trials. To this end, The Association for Frontotemporal Degeneration and The ALS Association supported a multi-stakeholder workshop (in Washington D.C., June 2024) to unify efforts to design a prevention trial for the population at elevated genetic risk for the phenotypic spectrum of C9orf72 disease. Here we describe recommendations emanating from this workshop for the selection of outcome measures, delineation of eligibility criteria, optimal use of biomarkers and digital health technologies, potential analytic frameworks and relevant regulatory considerations related to C9orf72 disease prevention trials. We also emphasize the importance of the amyotrophic lateral sclerosis and frontotemporal dementia communities working together in partnership with the C9orf72 repeat expansion carrier community, the regulatory authorities and the broader drug development community.
Comparative efficacy and procedural outcomes of pulsed field ablation vs. thermal ablation for paroxysmal atrial fibrillation: a systematic review and meta-analysis of randomized trials
Krishan, Satyam , Rehman, Taha , Agarwal, Siddharth , Agarwal, Siddharth , Rehman, Taha A. Zaka Ur , Asad, Zain Ul Abideen

Mayo Clinic

European Heart Journal Open | August 1, 2025 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/ehjopen/oeaf092 | PMID 40809739 Get It